title: Clinical-pathological conference: case 3.
authors.affiliation: Department of Oral and Maxillofacial Pathology, Tufts University School of Dental Medicine, Boston, MA 02111, USA. james.hall@tufts.edu
authors.forename: James M
authors.initials: JM
authors.lastname: Hall
authors.forename: Kevin R
authors.initials: KR
authors.lastname: Torske
authors.forename: Michael A
authors.initials: MA
authors.lastname: Kahn
authors.forename: Adele A
authors.initials: AA
authors.lastname: Moreland
authors.forename: Samuel L
authors.initials: SL
authors.lastname: Moschella
mesh_terms: D000328:Adult; D003622:Dapsone / Q000009:adverse effects; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000175:diagnosis; D007239:Infections / Q000175:diagnosis; D007896:Leishmaniasis / Q000175:diagnosis; D007917:Leprostatic Agents / Q000627:therapeutic use; D056006:Leprosy, Multibacillary / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology; D008297:Male; D008911:Minocycline / Q000627:therapeutic use; D009166:Mycobacterium leprae / Q000302:isolation & purification*; D015242:Ofloxacin / Q000627:therapeutic use; D010159:Palate / Q000473:pathology*; D011241:Prednisone / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D013322:Strongyloidiasis / Q000175:diagnosis; D016896:Treatment Outcome
chemical_list: D007917:Leprostatic Agents; D003622:Dapsone; D015242:Ofloxacin; D008911:Minocycline; D011241:Prednisone; D012293:Rifampin